Cargando…
The cost impact of disease progression to metastatic castration-sensitive prostate cancer
BACKGROUND: Metastatic prostate cancer (PC) is associated with declining survival rates and increased health care expenditure. However, there are few studies quantifying these increased costs. OBJECTIVE: To estimate overall health care resource utilization and costs associated with progression to me...
Autores principales: | Trinh, Quoc-Dien, Chaves, Leonardo Passos, Feng, Qi, Zhu, Julia, Sandin, Rickard, Abbott, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373041/ https://www.ncbi.nlm.nih.gov/pubmed/35471070 http://dx.doi.org/10.18553/jmcp.2022.28.5.544 |
Ejemplares similares
-
Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
por: Freedland, Stephen J., et al.
Publicado: (2021) -
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2021) -
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2022) -
Radical prostatectomy for high-risk prostate cancer | Opinion: YES
por: Reis, Leonardo O., et al.
Publicado: (2019) -
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
por: Ramaswamy, Krishnan, et al.
Publicado: (2020)